Evidence map›Paper›PMID 41081432›Full record

ArticleCancer immunology research2026

IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy.

Shayan C Avanessian, Renske J E van den Bijgaart, Nayvin W Chew, Valentina M Supper, Thao T Tang, Yuzheng Zhang, Ying-Qi Zhao, Kokoro Abe, Jordan Gauthier, Kevin C Barry

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shayan C Avanessian *Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-8883-0070
Renske J E van den Bijgaart *Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-0941-267X
Nayvin W ChewTranslational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0002-5363-5563
Valentina M SupperDepartment of Immunology, University of Washington School of Medicine, Seattle, Washington.ORCID 0000-0002-3726-1840
Thao T TangTranslational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0008-9456-1699
Yuzheng ZhangClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0005-6460-5871
Ying-Qi ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-2851-2257
Kokoro AbeImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0005-4822-8180
Jordan GauthierClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-5769-8409
Kevin C BarryTranslational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-1064-5964

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Dissecting the immunomodulatory effects of NK cells on immune responses to cancerR01CA283080 · NCI · FRED HUTCHINSON CANCER CENTER · PI Kevin C Barry · 2024 to 2026
$2.7M
American Cancer Society (ACS) RSG-23-1039729-01-IBCDMelanoma Research Alliance (MRA) 1040560National Cancer Institute (NCI) 1R01CA283080NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA283080
6 · The paper itself

Abstract

NK cells play a critical role in anticancer immunity through their direct cytotoxicity and production of cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L). NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. In this study, we show that NK cell production of Flt3l in the tumor is regulated by activation and that activation by IL2 and IL15 uniquely induced Flt3L expression in NK cells. In melanoma, IL2 signaling in NK cells led to increased Flt3L production, which boosted cDC1 abundance in the tumor and improved anti-PD-1 immunotherapy response. Furthermore, NK cell subsets differentially regulated Flt3l in the tumor, with CD11b-CD27+ NK cells in mouse tumors enriched for IL2 family signaling and upregulating Flt3l upon activation. Consistently, human CD56brightCD16- NK cells more strongly correlated with cDC1 and FLT3LG expression than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic study of NK cell regulation of FLT3LG and control of the NK cell-cDC1 axis provides insights and strategies for the development of more effective cancer immunotherapies.

Indexed as

Immune Checkpoint InhibitorsInterleukin-15Interleukin-2Killer Cells, NaturalMelanomaMembrane ProteinsProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorDendritic CellsHumansImmunotherapyMiceMice, Inbred C57BLSignal Transductionflt3 ligand proteinImmune Checkpoint InhibitorsInterleukin-15Interleukin-2Membrane ProteinsProgrammed Cell Death 1 Receptor

Identifiers

PMID41081432
PMCPMC12582536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.